drugset
drugset / Trial / NCT01033318

A Study of the Pharmacokinetics and Pharmacodynamics of MK1809 (1809-001)(COMPLETED)

NCT01033318 ↗

Phase 1 Completed 30 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The goal of this study is to identify at least one safe and well tolerated dose of MK1809 that has similar pharmacokinetic qualities as 100 mg losartan.

Timeline

Start
2007-09-11
Primary completion
2008-06-19
Completion
2008-06-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Losartan Other / unclassified 100 mg Oral
Subject MK1809 Unknown 2 mg Oral
Subject MK1809 Unknown 10 mg Oral
Subject MK1809 Unknown 25 mg Oral
Subject MK1809 Unknown 50 mg Oral
Subject MK1809 Unknown 100 mg Oral
Subject MK1809 Unknown 150 mg Oral
Subject MK1809 Unknown 210 mg Oral
Subject MK1809 Unknown 280 mg Oral

Indications

hypertensive disorder